While you want to make your children happy, you also want them to become grateful and appreciative adults. Find the perfect ...

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported ...

Real-time index price for TSX Canadian Dividend Aristocrats Index (TXDV), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Biotechnology Market OverviewThe Biotechnology Market report delivers crucial insights into the market's growth trajectory ...

Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...